Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Min Ren

Showing results (741-750 of 764) with videos related to

Pageof 77
Sort By:
Scientific Reports|November 19, 2015
Structural insights into HetR-PatS interaction involved in cyanobacterial pattern formationHai-Xi Hu, Yong-Liang Jiang, Meng-Xi Zhao, et al.
International Urology and Nephrology|January 22, 2017
Treatment of complicated urinary tract infection and acute pyelonephritis by short-course intravenous levofloxacin (750 mg/day) or conventional intravenous/oral levofloxacin (500 mg/day): prospective, open-label, randomized, controlled, multicenter, non-inferiority clinical trialHong Ren, Xiao Li, Zhao-Hui Ni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 28, 2015
A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid CancerMartin Schlumberger, Barbara Jarzab, Maria E Cabanillas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 15, 2015
Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with MelanomaDavid S Hong, Razelle Kurzrock, Jennifer J Wheler, et al.
Journal for Immunotherapy of Cancer|June 20, 2020
First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE<sub>2</sub>-receptor E-type 4 (EP4), in patients with advanced cancersDavid S Hong, Aparna Parikh, Geoffrey I Shapiro, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|May 11, 2025
Wireless In Situ Catalytic Electron Signaling-Mediated Transcriptomic Reprogramming for Neuron Regeneration via Adaptable AntennasHoi Man Iao, Chih-Ying Chen, Ya-Hui Lin, et al.
Small Science|April 11, 2025
Ophthalmic Tethered Gold Yarnball-Mediated Retained Drug Delivery for Eye Fundus Disease TreatmentShih-Jie Chou, Yi-Ping Yang, Min-Ren Chiang, et al.
Cancer|April 28, 2015
A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessmentMaria E Cabanillas, Martin Schlumberger, Barbara Jarzab, et al.
Lancet (London, England)|February 14, 2018
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trialMasatoshi Kudo, Richard S Finn, Shukui Qin, et al.
Rheumatology (Oxford, England)|December 20, 2011
Epidemiology of eight common rheumatic diseases in China: a large-scale cross-sectional survey in BeijingRu Li, Jian Sun, Li-Min Ren, et al.
Pageof 77

Showing results (741-750 of 764) with videos related to

Sort By:
Pageof 77
Scientific Reports|November 19, 2015
Structural insights into HetR-PatS interaction involved in cyanobacterial pattern formationHai-Xi Hu, Yong-Liang Jiang, Meng-Xi Zhao, et al.
International Urology and Nephrology|January 22, 2017
Treatment of complicated urinary tract infection and acute pyelonephritis by short-course intravenous levofloxacin (750 mg/day) or conventional intravenous/oral levofloxacin (500 mg/day): prospective, open-label, randomized, controlled, multicenter, non-inferiority clinical trialHong Ren, Xiao Li, Zhao-Hui Ni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 28, 2015
A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid CancerMartin Schlumberger, Barbara Jarzab, Maria E Cabanillas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 15, 2015
Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with MelanomaDavid S Hong, Razelle Kurzrock, Jennifer J Wheler, et al.
Journal for Immunotherapy of Cancer|June 20, 2020
First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE<sub>2</sub>-receptor E-type 4 (EP4), in patients with advanced cancersDavid S Hong, Aparna Parikh, Geoffrey I Shapiro, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|May 11, 2025
Wireless In Situ Catalytic Electron Signaling-Mediated Transcriptomic Reprogramming for Neuron Regeneration via Adaptable AntennasHoi Man Iao, Chih-Ying Chen, Ya-Hui Lin, et al.
Small Science|April 11, 2025
Ophthalmic Tethered Gold Yarnball-Mediated Retained Drug Delivery for Eye Fundus Disease TreatmentShih-Jie Chou, Yi-Ping Yang, Min-Ren Chiang, et al.
Cancer|April 28, 2015
A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessmentMaria E Cabanillas, Martin Schlumberger, Barbara Jarzab, et al.
Lancet (London, England)|February 14, 2018
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trialMasatoshi Kudo, Richard S Finn, Shukui Qin, et al.
Rheumatology (Oxford, England)|December 20, 2011
Epidemiology of eight common rheumatic diseases in China: a large-scale cross-sectional survey in BeijingRu Li, Jian Sun, Li-Min Ren, et al.
Pageof 77